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The intracellular anaplastic lymphoma kinase (ALK) fragment shows striking homology with
members of the insulin receptor family and was initially identiﬁed as an oncogenic fusion
protein resulting from a translocation in lymphoma andmore recently in a range of cancers.
The full-lengthALK transmembrane receptor of∼220 kDawas identiﬁed based on this initial
work. This tyrosine kinase receptor and its ligands, the growth factors pleiotrophin (PTN)
and midkine (MK) are highly expressed during development of the nervous system and
other organs. Each of these genes has been implicated inmalignant progression of different
tumor types and shown to alter phenotypes aswell as signal transduction in cultured normal
and tumor cells. Beyond its role in cancer, theALK receptor pathway is thought to contribute
to nervous system development, function, and repair, as well as metabolic homeostasis
and the maintenance of tissue regeneration. ALK receptor activity in cancer can be up-
regulated by ampliﬁcation, overexpression, ligand binding, mutations in the intracellular
domain of the receptor and by activity of the receptor tyrosine phosphatase PTPRz. Here
we discuss the evidence for ligand control of ALK activity as well as the potential prognostic
and therapeutic implications from gene expression and functional studies. An analysis of
18 published gene expression data sets from different cancers shows that overexpression
of ALK, its smaller homolog LTK (leukocyte tyrosine kinase) and the ligands PTN and MK
in cancer tissues from patients correlate signiﬁcantly with worse course and outcome of
the disease.This observation together with preclinical functional studies suggests that this
pathway could be a valid therapeutic target for which complementary targeting strategies
with small molecule kinase inhibitors as well as antibodies to ligands or the receptors may
be used.
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Receptor kinase activities are controlled by expression levels as well
as the binding of their cognate ligands (Schlessinger and Ullrich,
1992; Schlessinger, 2000). Furthermore, mutations can inhibit or
enhance constitutive receptor activity as well as ligand-dependent
signaling. The anaplastic lymphoma kinase (ALK) tyrosine kinase
receptor ﬁts into this general model though the kinase was dis-
covered as part of an oncogenic fusion protein of the intracellular
portion of ALK with nucleophosmin (NPM) induced by a t(2,5)
translocation (Morris et al., 1994). A series of other fusion part-
ners with the intracellular ALK portion were discovered thereafter
(Duyster et al., 2001), most recently as a transforming oncogene
in a small subset of lung cancers. These fusion proteins have gath-
eredmuch interest as a therapeutic target for smallmolecule kinase
inhibitors and are reviewed elsewhere in this issue. The intracellu-
lar kinase portion of ALK show ∼50% homology and overlapping
signaling paths with the insulin receptor family, including the sig-
naling through the adaptor molecule insulin receptor substrate-1
(IRS-1), SHC, and Grb2 (see Figure 1; Ueno et al., 1996; Stoica
et al., 2001; Crockett et al., 2004; Kuo et al., 2007). The full-length
ALK was identiﬁed as a transmembrane receptor and its highest
expression was found in the developing central and peripheral
nervous system (Iwahara et al., 1997; Morris et al., 1997). Expres-
sion of the full-length protein was also found in cultured normal
cells and in cancer cell lines (Stoica et al., 2001). It is notewor-
thy that the extracellular domain (ECD) of ALK shares signiﬁcant
homology over a ∼40% stretch with the leukocyte tyrosine kinase
(LTK) and is otherwise a unique protein (Duyster et al., 2001; see
Figure 1).
LIGANDS OF THE ALK RECEPTOR
Our studies of growth factors and their signal transduction con-
nected the ALK receptor with the growth factor pleiotrophin
(PTN):We had puriﬁed and characterized PTN from supernatants
of human breast cancer cells (Fang et al., 1992; Wellstein et al.,
1992) and deﬁned a signaling pathway of this protein (Souttou
et al., 1997). PTN is highly expressed in the nervous system in
addition to its high expression in some cancers (Li et al., 1990;
Fang et al., 1992). From this we reasoned, that the likely receptor
would also be expressed in brain tissues. To identify a receptor for
PTN, we thus used a phage library that displayed human brain
cDNAs as fusion proteins on the phage surface. Puriﬁed PTN was
immobilized as a bait protein, and the phage library was panned
against this bait. From this unbiased screen we identiﬁed a phage
insert sequence that matched with a region in the ECD of the ALK
receptor that was only cloned a year earlier (Iwahara et al., 1997;
Morris et al., 1997). This amino acid stretch in ALK thus deﬁned
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FIGURE 1 | Anaplastic lymphoma kinase (ALK) receptor domains,
pathways, inhibitors, and homologies. Amino acid positions ﬂanking
different domains in ALK are shown. Small molecule kinase inhibitors and
antibodies are indicated as is the ALK translocation breakpoint. The amino
acid sequence overlap and homology of the ECD of LTK is shown. Also, the
homology with the closest related kinases is indicated for the kinase
domain. Mutations discussed in the text and also in (Wellstein andToretsky,
2011). The LBD was identiﬁed by phage display of a brain cDNA library
against immobilized PTN (Stoica et al., 2001). The LBD is within an MAM
domain that is frequently found in the ECDs of a diverse family of
transmembrane proteins (Prosite data base PDOC 00604). SigP, signal
peptide; LBD, ligand binding domain; ECD, extracellular domain; ICD,
intracellular domain; TM, transmembrane domain; PTN, pleiotrophin; MK,
midkine; LTK, leukocyte tyrosine kinase; IGF1R, insulin-like growth factor 1
receptor; InsR, insulin receptor.
the ligand binding domain (LBD) in the receptor (Figure 1; Stoica
et al., 2001). A recombinant ECD of ALK incubated with immobi-
lized PTN validated the ﬁndings with the phage. Also, a titration
curve of PTN against the immobilizedALK ECD showed saturable
binding with an EC50 of PTN around 1 ng/ml. In a complemen-
tary, unbiased screen, mass spectrometry analysis of cancer cell
supernatants identiﬁed PTN as the major ligand for the ALK ECD
that had been immobilized on SELDI mass spectrometry chips
(Stoica et al., 2001). Finally, a series of receptor binding studies
in intact cells completed the analysis: equilibrium binding of 35S-
PTN to ALK that was expressed in 32D cells was inhibited by an
antibody to PTN as well as an antibody to the LBD, an excess
of the ECD protein and by an excess of unlabeled PTN pro-
tein (Figures 2A,B). This data support a speciﬁc ligand-receptor
interaction. The interaction was further quantitated by receptor
binding studies in ALK transfected 32D cells with 35S-PTN. The
KD of 30 pM (= 0.5 ng/ml) derived from a Scatchard analysis
(Figure 2B) matched well with the EC50 of puriﬁed PTN in earlier
growth assays and connected protein interactions with functional-
ity (Wellstein et al., 1992). Also, a series of phosphorylation studies
with different intracellular substrates showed that signal transduc-
tion initiated as early as 1 min after addition of the PTN ligand
(Stoica et al., 2001). In parallel experiments the PTN homolog
midkine (MK) was studied for its signal transduction and recep-
tor interaction with ALK. We observed a somewhat lower afﬁnity
of MK for the ALK receptor (∼100 pM). MK binding was com-
peted by unlabeled PTN in a concentration range that matches
the afﬁnity of PTN (Figure 2C). Furthermore, signal transduc-
tion of MK as well as stimulation of colony formation induced by
exogenously added MK were inhibited by monoclonal antibodies
raised to the ALK LBD (Stoica et al., 2002). From these data we
conclude that MK and PTN are activating ligands for the ALK
receptor.
THE PHYSIOLOGIC ROLE OF THE PTN/MK–ALK AXIS
A well established paradigm is the close relationship of pathways
that control malignant progression and pathways that contribute
to tissue repair and tissue maintenance. Furthermore, molecules
that participate in physiologic development of a particular tissue
are likely to contribute signiﬁcantly to its repair after injury as
well as to its malignant progression. With the discovery that new
neurons and glia are produced throughout life from undifferen-
tiated, pluripotent precursor cells, it became obvious that such
stem cells may also participate in the initiation and progression of
nervous system tumors (Holland, 2001; Vescovi et al., 2006). PTN,
MK, and ALK are highly expressed in the nervous system during
development. A recent report connected MK and ALK signaling
to sympathetic neuron growth during development and aberrant
signaling to neuroblastoma predisposition (Reiff et al., 2011). The
increased expression of PTN, MK, and ALK in more advanced
stages of cancers of glial origin was shown earlier (see below),
and matches with a partial reversion of tumor cells to a precursor
phenotype that was operational during development.
Recent studies also show a signiﬁcant role of the PTN–ALK
interaction during neuronal injury (Mi et al., 2007) and thus con-
nect this growth factor-receptor pathway to adult tissue repair.
Interestingly, germ line inactivation of ALK, PTN, or MK did
not impact on overall embryo survival or cause gross patholo-
gies. However, a more detailed analysis revealed subtle alterations
in animal behavior, memory, and fertility in knockout animals
(Muramatsu et al., 2006; Zou et al., 2006; Bilsland et al., 2007;
reviewed in Li and Morris, 2007). Also, more recent studies in
MK knockout mice showed that MK counteracts the deposition
of amyloid plaques suggesting a role in repair (Muramatsu et al.,
2011). PTN knockout mice revealed altered amphetamine-seeking
behavior (Gramage et al., 2010) and this is complemented by a role
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FIGURE 2 | Binding of PTN and MK to the ALK receptor in intact
cells. (A) Competition for ALK binding of 35S-PTN in 32D/ALK cells.
Competitors were: anti-PTN antibody, anti-ECD antibody, ECD protein,
unlabeled PTN. (B)Titration of equilibrium binding of 35S-PTN to
32D/ALK and to 32D/control cells. A Scatchard analysis of speciﬁc binding
is shown in the inset. Modiﬁed from Stoica et al. (2001). (C) Competition
of PTN for ALK receptor binding of 35S-MK. Binding of 35S-MK to
32D/ALK (ﬁlled symbols) and 32D/control cells (open symbols) was
competed by different concentrations of PTN. Modiﬁed from Stoica et al.
(2002).
of ALK in behavioral responses to ethanol (Lasek et al., 2011).
If one extrapolates from these studies in rodents to potential
side effects of targeted therapies, the subtle phenotypic outcomes
of gene deletions suggests that therapeutic targeting may not
cause severe side effects. It is a matter of conjecture to predict
whether higher nervous system functionsmay be impacted by such
treatments.
ALK, LTK PTN, AND MK EXPRESSION IN CANCER
EXPRESSION IN THE STROMA OF CANCER TISSUES
The cross-talk between cancer cells and stromal cells is a cru-
cial element of malignant progression and is required for cancer
cell migration, invasion into the vasculature, the recruitment of
inﬂammatory cells, and the establishment and expansion of organ
metastases. The scheme in Figure 3 illustrates this. To assess
expression of the PTN–ALK pathway genes in stromal tissues,
we analyzed several data sets from microdissection and transcrip-
tome analysis of cancer and normal stroma. Finak et al. (2008)
reported an analysis of stromal gene expression in a breast tissue
set. Analysis of their data shows a signiﬁcant up-regulation of ALK
(p = 5 × 10−8), LTK (p = 3 × 10−4), and PTN (p = 0.002) in the
stroma of breast cancers relative to the stroma of normal breast
tissues. An analysis of the stroma of pancreatic duct adenocarci-
noma showed only LTK (p = 5 × 10−4) and PTN (p = 0.002)
signiﬁcantly up-regulated relative to normal pancreatic stromal
tissues (Buchholz et al., 2005). No signiﬁcant changes were seen
in a further analysis of breast tissues (Karnoub et al., 2007). These
data sets were accessed through the Oncomine data base (Rhodes
et al., 2004, 2007).
FIGURE 3 | Cross-talk between stromal and cancer cells via the
PTN/MK–ALK pathway. PTN and MK are heparin-binding proteins
released from cancer or stromal cells. They can bind at nanomolar afﬁnity to
glycosaminoglycans (GAGs) such as the heparan sulfate side chains of
proteoglycan (HSPG) as well as chondroitin sulfate (CS; Deepa et al., 2002).
CS is proposed as a co-receptor for MK (Muramatsu, 2010) as are other
GAGs (Li et al., 2010). Also N -syndecan could function as such a co-receptor
(Raulo et al., 1994). Both ligands and receptor can be found up-regulated in
the stroma of cancer as well as in cancer epithelia (see text).
BRAIN TUMORS
The normal developmental expression pattern of the ligands PTN
and MK in different tissues overlap to some extent with the ALK
receptor. The overall highest levels are found in the central and
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peripheral nervous system during mid to late gestation (Li et al.,
1990; Iwahara et al., 1997). In normal adult tissues, however, only
limited expression of the full-lengthALK receptor, PTNorMKwas
seen but overexpression of these genes was reported in a number
of human cancers including brain tumors (Schulte and Wellstein,
1997; Mentlein and Held-Feindt, 2002; Powers et al., 2002; Peria
et al., 2007). More recently,we evaluated the expressionofALKand
PTN mRNA in normal brain and 34 glial tumor tissues using in
situ hybridization of serial sections of surgical specimen. Overall,
only the most aggressive, high grade tumors, i.e., GBM (glioblas-
toma multiforme) and anaplastic oligodendroglioma showed an
increased expression of PTN and ALK mRNA relative to nor-
mal brain tissues, relative to adjacent brain tissues and relative
to low grade tumors (p < 0.01). Also there was a direct correlation
between ALK and PTN mRNA expression (p < 0.001) that was
also visible when superimposing serial sections of the tissues that
had been hybridized with different probes (Stylianou et al., 2009).
An analysis of published gene expression data sets corroborates
this ﬁnding (Table 1; Rhodes et al., 2004, 2007): GBM express sig-
niﬁcantly higher levels of PTN and ALK than normal brain tissues
and astrocytoma or oligodendroglioma. Interestingly, the phos-
phatase PTPRz that is thought to interact with the ALK pathway
(see below) is also signiﬁcantly up-regulated in all of these cancer
specimen relative to normal brain.
GENE EXPRESSION AND DISEASE OUTCOME
Comparisons of gene expression levels in clinical cancer specimen
and disease outcomes can be useful for disease prognosis and in
assessing whether a gene may function as driver of malignant pro-
gression: a positive correlation between higher expression levels
of a given gene and poor disease outcome provides at the least a
marker of poor prognosis (Mischel et al., 2003). Beyond prognosis,
a correlation between gene up-regulation and poor outcome may
also indicate that the gene of interest is a driver of the malignancy.
HER2/erbB2 expression in breast cancer is one of the best known
examples of this paradigm with high levels of expression indi-
cating poor prognosis and at the same time favorable response
Table 1 | Brain tumor gene expression.
Expression levels relative to normal brain
(n = 23; data from Sun et al., 2006)
AC ODG GBM
n 26 50 77
PTN 0.0004 <0.0001 <0.0001
MK <0.0001 0.0001 <0.0001
ALK NS NS 0.013
PTPRz <0.0001 <0.0001 <0.0001
mRNA expression of PTN, MK, ALK, PTPRz in normal brain versus brain tumors
from the Oncomine data basewere used for the analysis.The number of patients
in each group and the p-value for the comparisons of expression levels of
the respective gene are indicated. NS, not signiﬁcant, p > 0.05. AC, astrocy-
toma; ODG, oligodendroglioma; GBM, glioblastoma multiforme. Modiﬁed from
Stylianou et al. (2009).
to antibody therapy with anti-HER2 antibody treatment, e.g.,
with trastuzumab. Here we used data extracted from published
genome-wide expression analyses to avoid a bias in favor of the
gene sets of interest. We then assessed whether there is a relation-
ship between tumor expression of the genes and disease outcome.
To illustrate this concept, data from two brain tumor studies are
depicted in Figure 4 using published data sets (Shai et al., 2003;
Phillips et al., 2006). For this, the respective gene expression arrays
of surgical tumor specimen at the time of diagnosis were searched
for the levels of PTN or ALK mRNA. Gene expression is provided
on a log scale in arbitrary units generated after normalization by
the data base provider to allow for a comparisons across platforms.
PTNorALKmRNA levels obtained from the tumor specimenwere
then separated into two groups, i.e., for those patients who were
still alive 3 or 5 years after the initial diagnosis versus those patients
who had perished by that time. The respective survival data were
available for these data sets. The comparison of gene expression
in these two groups shows that patients with higher expression
levels of PTN or of ALK in their brain tumors had perished by
the chosen time whereas patients with lower levels were still alive.
Thus, higher expression of PTN or of ALK is associated with poor
outcome of the disease (Figure 4).
In a systematic analysis of studies present in the Oncomine data
base we applied this approach and found 18 independent gene
expression data sets of different cancers that also provided disease
outcomes, showed expression of all genes of interest and were
thus suitable for the analysis. The respective outcome measures
and correlation with the expression of ALK, LTK, PTN, and MK
are shown in Table 2 (Freije et al., 2004). In this series at least one
of the PTN–ALK pathway genes showed a signiﬁcant correlation
between high expression level and poor outcome for each of the
cancers represented. For several of the cancers, overexpression of
more than one of the genes in this pathway were related to poor
outcome. Obviously, this analysis is limited by the available gene
FIGURE 4 | Expression of PTN or ALK in brain tumors in patients with
different survival. Data from the Oncomine data base showing the
expression levels of PTN (Phillips et al., 2006) or of ALK (Shai et al., 2003) in
brain tumor samples. Tumor expression data were separated into those
from patients alive or dead at 5 years (PTN) or 3 years (ALK) respectively.
The data are presented as log values after normalization to the respective
gene expression array and are shown as provided by Oncomine. Further
studies are provided inTables 1 and 2.
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Table 2 | Disease outcomes relative to gene expression of ALK, LTK, PTN, and MK in clinical cancer specimen.
Study name in
Oncomine
Cancer subtype Outcome
measure
ALK LTK PTN MDK
Brain
tumors
Phillips brain Astrocytoma Dead at 3Years
Dead at 5Years
0.045
–
–
–
0.047
5.47E-05
–
0.007
French brain Anaplastic
Oligodendroglioma
Dead at 3Years
Dead at 5Years
–
–
–
–
0.033
0.034
–
–
Freije brain Anaplastic
Oligodendroglioma
Dead at 3Years – – 0.019 –
Freije brain Glioblastoma Dead at 1Year – 2.89E-04 – –
Pomeroy
brain
Medulloblastoma Dead at 1Year – – 0.004 –
Breast
cancer
Boersma
breast
Ductal breast
carcinoma epithelia
Dead at 5Years 0.029 – – –
Desmedt
breast
Invasive ductal
carcinoma
Dead at 5Years 0.003 – – –
Pawitan breast Breast carcinoma Dead at 3Years
Dead at 5Years
1.30E-04
7.90E-04
–
–
–
–
–
–
Loi breast Breast carcinoma Metas. at 3Years
Metas. at 5 years
0.016
7.37E-04
0.034
–
–
–
–
–
Minn breast 2 Breast carcinoma Metas. at 1Year
Metas. at 3Years
Metas. at 5Years
0.036
0.011
7.49E-04
–
–
0.041
–
–
–
–
–
–
Colon
cancer
Kurashina
colon
Colon
Adenocarcinoma
Dead at 1Year
Dead at 3Years
–
–
0.008
0.002
–
0.032
–
0.028
TCGA 2
colorectal
Colon
Adenocarcinoma
Dead at 1Year – 0.033 – –
Smith
colorectal
Colorectal
Adenocarcinoma
Dead at 5Years 0.009 – – 0.025
Lung
cancer
Bild lung Lung
Adenocarcinoma
Dead at 1Year
Dead at 3Years
4.35E-05
0.013
–
0.037
–
–
–
–
Melanoma Xu melanoma Melanoma Metastasis
Dead at 3Years
0.017
–
–
0.036
–
–
0.23
–
Ovarian
cancer
Bild ovarian Ovarian carcinoma Dead at 1Year 0.041 – – –
Tothill
ovarian
Ovarian serous
Adenocarcinoma
Recur. at 3Years
Recur. at 5Years
0.003
0.018
–
–
–
–
–
–
Prostate
cancer
Taylor
prostate 3
Prostate carcinoma Recur. at 1Year
Recur. at 3Years
Recur. at 5Years
0.021
–
0.037
0.003
–
–
–
–
–
0.014
0.035
–
All studies Separate
Studies n = 18
Studies (out of 18) that showed at least one
outcome correlation of < 0.05
12 8 5 5
Measures of disease outcome include overall survival (alive or dead at 1, 3, or 5 years), disease free or disease recurrence and metastasis free or occurrence of
metastasis. mRNA expression levels of ALK, LTK, PTN, and MK were obtained and compared for the available disease outcomes. The respective p-value for these
comparisons of expression levels with different disease outcomes are indicated. Details to the respective studies are available under the study names indicated in
the ﬁrst column (Oncomine.org; Rhodes et al., 2004, 2007). A total of 18 suitable studies were found and each of the p-values shown indicates a signiﬁcant positive
association of higher expression of the respective gene with worse outcome.
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expression data obtained from surgical tumor specimen and the
necessary follow-up of the disease outcome. At the very least, this
unbiased analysis supports the hypothesis that the ALK pathway
may be a valid target for therapeutic interventions in cancers of
different subtypes andorgans including thenervous system, breast,
lung, colon, ovary, prostate, and in melanoma. Limitations of the
analysis are due to the available data sets and/or outcomemeasures.
FUNCTIONAL PRECLINICAL STUDIES IN CANCER
We have previously shown that the ALK protein and mRNA
are overexpressed in some tumors of glial origin and shown
that ribozyme-mediated depletion of ALK mRNA from human
U87MG glioblastoma cells resulted in apoptosis of xenograft
tumors in mice (Powers et al., 2002). Different laboratories have
demonstrated the signiﬁcance of PTN as a growth and survival
factor for different solid tumors including melanoma (Czubayko
et al., 1996), pancreatic cancer (Weber et al., 2000), glioblastoma
(Grzelinski et al., 2006), and multiple myeloma (Chen et al., 2007)
to name a few. More recent studies show that MK contributes
to glioma progression through ALK signaling and thus ren-
ders glioma cells resistant to antitumoral effects of cannabinoids
(Lorente et al., 2011; reviewed in Velasco et al., 2012). Further-
more, in lung adenocarcinoma, menin and polycomb-mediated
repression of PTN transcription and is proposed as an epigenetic
mechanism that controls the PTN–ALK signaling pathway and
hence can inhibit lung cancer progression (Gao et al., 2009).
ALK AND CANCER CELL INVASION
The invasive capability of cells is a hallmark of malignancy and
we thus studied the contribution of ALK signaling to tumor cell
invasion of an endothelial monolayer (Stylianou et al., 2009). In
a co-culture system a conﬂuent endothelial cell monolayer was
grown and then exposed to tumor cells (Figure 5). Electrical
resistance of the monolayer was monitored as a real-time indi-
cator of invasion (Keese et al., 2002). We used the human U87MG
glioblastoma cells that express PTN with human umbilical vein
endothelial cells (HUVEC) that express ALK (Stoica et al., 2001).
In the invasion assay U87MG cells showed a continuous inva-
sion that was prevented by inclusion of an anti-ALK antibody
(Stylianou et al., 2009). It is noteworthy that proliferation of the
tumor cells is not affected by either by depletion of ALK (Powers
et al., 2002) or by blockade with an antibody. Obviously, U87MG
invasion of stromal tissues can be inhibited by targeting of the
PTN–ALK interaction. An ALK-dependent invasive phenotype
was recently also described in vivo in a mouse model of pancreatic
neuroendocrine carcinogenesis (Chun et al., 2010).
ALK–PTPRz CROSS-TALK AND PTN ISOFORMS
In addition to the binding to theALK tyrosine kinase, PTNandMK
also bind to a receptor-type protein tyrosine phosphatase PTPz,
PTPRz, PTPRZ1, or RPTPb/z (Maeda et al., 1996, 1999; Maeda
and Noda, 1998). Work from T. F. Deuel’s laboratory showed
that PTN inactivates PTPz thereby controlling the activity of tyro-
sine kinases (Meng et al., 2000; Perez-Pinera et al., 2006), possibly
also impacting ALK signaling (Perez-Pinera et al., 2007). Further-
more, the MK–PTPz interaction was shown to induce osteoblast
cell migration as well as neuronal survival (Owada et al., 1999;
FIGURE 5 | Effect of anti-ALK antibody on U87 GBM cell invasion of an
endothelial cell monolayer. Endothelial cell monolayers were formed on
electrodes and the intactness of the monolayer was monitored by electrical
impedance sensing. Upon addition of the U87 cells the monolayer is
disrupted and this is reﬂected in real-time as a decrease in electrical
resistance of the monolayer. Inclusion of an anti-ALK antibody prevents this
disruption (Stylianou et al., 2009).
Qi et al., 2001; Sakaguchi et al., 2003). Interestingly, two iso-
forms of PTN (18 and 15 kDa) were identiﬁed more recently and
appear to have distinct roles and intracellular signaling transduc-
tion pathways with respect to ALK and PTPRz (Lu et al., 2005).
The PTN isoforms work at different protein concentrations with
the 15 kDa isoform being more potent for ALK and the 18 kDa
isoform that interacts with PTPRz being less potent. To address
this distinction of pathways in vivo, A. Höke’s laboratory at Hop-
kins evaluated the contribution of PTN and potential receptors to
neuronal repair (Mi et al., 2007). The laboratory had observed a
striking up-regulation of PTN during spinal motor neuron den-
ervation and sought to identify the driver pathway. Only ALK
was up-regulated from a survey of potential receptors described
for PTN. Antibody blockade revealed that ALK was the mediator
of trophic activities of PTN in motor neurons. This is corrob-
orated by a later study where PTN induced neurite outgrowth
and signal transduction that were attenuated by anti-ALK anti-
bodies, but not anti-PTPRz antibodies suggesting that ALK is
involved in the PTN signaling on neural development (Yanagisawa
et al., 2010). As mentioned above deposition of amyloid plaques
(Muramatsu et al., 2011), altered amphetamine-seeking behavior
(Gramage et al., 2010) and behavioral responses to ethanol (Lasek
et al., 2011) were reported for MK, PTN, and ALK knockouts.
An interesting connection between ligand-dependent ALK signal-
ing, sympathetic neurogenesis, and neuroblastoma was provided
recently in a study on the timing of sympathetic neurogenesis.
The Rohrer laboratory showed that neurogenesis is controlled
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by MK–ALK and proposed that this may explain some of the
ligand-mediated, ALK-dependent neuroblastoma predisposition
(Reiff et al., 2011).
Overall, these reports suggest a crucial role of the PTN/MK–
ALK axis in the genesis, repair and function of nervous system
tissues as well as the initiation of malignancies. Cross-talk with
the receptor tyrosine phospatase PTPRz appears to modulate
signaling.
GLYCOSAMINOGLYCANS AND HEPARAN SULFATE
PROTEOGLYCANS
Pleiotrophin andMKare heparin-binding growth factors and their
interaction with proteoglycans thus also impacts on their biologic
activity (Li et al., 2007; Sugahara and Mikami, 2007), reminiscent
of the impact of glycosaminoglycans (GAGs) on the signaling of
other heparin-binding growth factors, most prominently FGFs
(reviewed in Ornitz, 2000; Powers et al., 2000). In support of a role
of GAGs for PTN–MK function, a recent study showed that a frag-
ment of PTN (amino acids 65 to 97) binds to the GAG co-receptor
of FGF2 and PTN, and inhibits the mitogenic and tumorigenic
activities of both growth factors (Hamma-Kourbali et al., 2008).
This may also explain the dominant-negative effect described for
PTN fragments (Zhang et al., 1997; Chang et al., 2006). Also, chon-
droitin and dermatan sulfates (CS/DS) can bind PTN and present
it to high afﬁnity receptors (Bao et al., 2005) and more recent stud-
ies demonstrate that PTN is dependent on CS/DS binding for its
neurite outgrowth activity (Li et al., 2007; Sugahara and Mikami,
2007): antibodies against PTN or ALK inhibited the neuritogen-
esis induced by growth factors bound to the CS/DS chains, and
thus revealed the involvement of PTN and ALK. It is noteworthy
that the aforementioned receptor tyrosine phosphatase PTPRz is
a CS proteoglycan which may explain the tight binding of PTN or
MK and its co-receptor function in growth factor signaling.
ALK MUTATIONS AND LIGAND SIGNALING
Activating mutations in the ALK receptor were found associ-
ated with familial neuroblastoma, a fatal childhood cancer (Chen
et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008;
Mossé et al., 2008). The identiﬁcation of ALK mutations as poten-
tial drivers in neuroblastoma is signiﬁcant for a portion of this
cancer though overexpression of ALK may make a larger con-
tribution to the malignant progression. Indeed, a recent study
shows that high levels of ALK expression supersede mutations
of the receptor as a determinant of poor outcome of primary
neuroblastoma (Schulte et al., 2011). This could be due to the
activity of endogenous ligand that will parallel the receptor level
as suggested by growth inhibition even after depletion of wild-
type ALK (Kishida et al., 2012).
Although ALK mutations in neuroblastoma can only account
for small survival differences due to their low overall incidence,
the ALK F1174 mutation (in contrast to the ALK R1275 mutation)
coincideswith ameasurablyworse outcome. This supports a possi-
ble direct impact of the F1174 mutant on signaling and malignant
progression. Whilst stratiﬁcation of outcomes by ALK expression
levels showed signiﬁcantly worse outcome with high ALK expres-
sion, multigene analyses may provide a more robust predictor and
more detailed understanding of pathways that are activated. From
that, one would hope to inform the use of a different drug or of
drug combinations.
CONCLUSION
Targeting of the PTN/MK–ALK signaling pathway may provide
a new, mechanism-based approach to the treatment of cancers
that show activation of the pathway either due to high expression
levels of either these molecules or less well deﬁned mechanisms.
It is conceivable that a combination of antibody targeting of lig-
ands or receptor plus small molecule kinase inhibitors may act
synergistically and generate a better therapeutic outcome. Preclin-
ical ﬁndings suggest only subtle side effects from targeting this
pathway.
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